Promising Alzheimer’s treatment options lead to expanded PET scan recommendations
By
Aaron Dorman
Jul 24, 2023
CMS is now recommending expanding coverage for PET scans by lifting the current single-test limit.
‘Elderverse’ concept could serve as a VR social hub for intrepid seniors, Mynd CEO says
By
Aaron Dorman
Jan 17, 2024
The newly unveiled “elderverse” starts users out on a lush VR coastline, from which they can jump to entertainment or therapy options.
AI-driven speech analysis firm working to diagnose Alzehimer’s, Huntington’s
By
Aaron Dorman
Jun 27, 2023
A speech analysis software company is using Voice AI to diagnose depression and anxiety, and diseases like Alzheimer’s and Huntington’s could be next.
Americans ‘dangerously’ underestimate healthcare costs, challenges in retirement planning
By
Kimberly Bonvissuto
Sep 21, 2023
Americans “dangerously” underestimate the effects that healthcare costs and challenges may have on their retirement plans, including planning for a stay in a long-term care facility, according to the...
Health plans ‘like a deer in headlights’ when it comes to addressing dementia costs: report
By
Kimberly Bonvissuto
Dec 13, 2023
A new report on how health plan leaders view Alzheimer’s disease and related dementias reveals that despite awareness of skyrocketing costs, health plans are “like a deer in headlights,” unsure how...
Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.
Eight in 10 seniors see wisdom of dementia screening
Jul 20, 2023
Only about one in five has had such screening in the past year, however.
Aegis Living, SLR recognized for achieving elevated memory care standards
By
Kimberly Bonvissuto
Feb 26, 2024
Two assisted living and memory care providers have earned certifications for meeting elevated standards of care for people living with dementia.
Senior living asking rates hit near-record highs in second quarter
By
Kimberly Bonvissuto
Sep 12, 2023
Asking rates were at near-record highs for senior living communities in the second quarter, according to a new report from NIC MAP Vision.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.